Cancer Health Center
Kaposi’s Sarcoma - Immunosuppressive Treatment Related Kaposi’s Sarcoma
Some patients with Kaposi’s sarcoma have noted spontaneous and lasting remissions following discontinuation of immunosuppressive therapy. In managing these patients, if immunosuppressive therapy is not critical, its discontinuation is a reasonable first step.
STANDARD TREATMENT OPTIONS:
- Discontinue immunosuppressive therapy (often results in tumor regression). This option is critically important in patients who are receiving immunosuppressive drugs, as in the case of certain transplant patients.
- Radiation therapy (for disease limited to skin).[1,2,3,4]
- Chemotherapy, single or multiple drug: Most systemic chemotherapy trials in Kaposi’s sarcoma patients have been carried out in the African and epidemic varieties. See the section on the treatment of Epidemic Kaposi’s Sarcoma. The applicability of the results of these trials to Kaposi’s sarcoma in immunosuppressed patients is unknown.
References:
- Cohen L: Dose, time, and volume parameters in irradiation therapy of Kaposi's sarcoma. Br J Radiol 35(415): 485-488, 1962.
- Hamilton CR, Cummings BJ, Harwood AR: Radiotherapy of Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 12 (11): 1931-5, 1986.
- Lo TC, Salzman FA, Smedal MI, et al.: Radiotherapy for Kaposi's sarcoma. Cancer 45 (4): 684-7, 1980.
- Nisce LZ, Safai B, Poussin-Rosillo H: Once weekly total and subtotal skin electron beam therapy for Kaposi's sarcoma. Cancer 47 (4): 640-4, 1981.
WebMD Public Information from the National Cancer Institute
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER
Last Updated:
December 13, 2006
This information is not intended to replace the advice of a doctor.
Healthwise disclaims any liability for the decisions you make based on this
information.
Some material in CancerNet™ is from copyrighted publications of the respective copyright claimants. Users of CancerNet™ are referred to the publication data appearing in the bibliographic citations, as well as to the copyright notices appearing in the original publication, all of which are hereby incorporated by reference.



